RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trialResearch in context

RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trialResearch in context

Summary: Background: Glypican-3 (GPC3) is a well-characterized hepatocellular carcinoma (HCC)-associated antigen and a promising target for HCC treatment. CT017 CAR T cells were engineered to co-express CAR-GPC3 and runt-related transcription factor 3 (RUNX3), which triggers CD8+ T-cell infiltratio...

Full description

Bibliographic Details
Main Authors:	Qihan Fu, Yi Zheng, Weijia Fang, Qingwei Zhao, Peng Zhao, Lulu Liu, You Zhai, Zhou Tong, Hangyu Zhang, Meihua Lin, Xudong Zhu, Huamao Wang, Yumeng Wang, Zhen Liu, Daijing Yuan, Xuanwen Bao, Wanwan Gao, Xiaomeng Dai, Zonghai Li, Tingbo Liang
Format:	Article
Language:	English
Published:	Elsevier 2023-09-01
Series:	EClinicalMedicine
Subjects:	CAR T-cell therapy Hepatocellular carcinoma Safety of CAR T-cell therapy in HCC GPC3-targeted CAR T cells Immunotherapy for advanced HCC
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589537023003528

Similar Items

Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology
by: Keming Lin, et al.
Published: (2024-04-01)

CRISPR in Targeted Therapy and Adoptive T Cell Immunotherapy for Hepatocellular Carcinoma
by: Palaz F, et al.
Published: (2024-05-01)

Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma
by: Bryan Mckiver, et al.
Published: (2020-12-01)

Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy
by: Katharina Eva Ruppel, et al.
Published: (2022-03-01)

Exploring Glypican-3 as a Molecular Target in Hepatocellular Carcinoma: Perspectives on Diagnosis and Precision Immunotherapy Strategies
by: Alireza Tojjari, et al.
Published: (2024-07-01)

The role of MSCs and CAR-MSCs in cellular immunotherapy
by: Lun Yan, et al.
Published: (2023-08-01)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
by: Kevin Pan, et al.
Published: (2022-03-01)

Pan-cancer analysis and the oncogenic role of Glypican 1 in hepatocellular carcinoma
by: Li Cao, et al.
Published: (2024-07-01)

Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy
by: Guangtan Du, et al.
Published: (2024-07-01)

CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity
by: Yaojie Kong, et al.
Published: (2025-01-01)

Approved CAR-T therapies have reproducible efficacy and safety in clinical practice
by: Daniel Goyco Vera, et al.
Published: (2024-12-01)

CAR-engineered T cell therapy as an emerging strategy for treating autoimmune diseases
by: Jovana Vukovic, et al.
Published: (2024-10-01)

Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma
by: Tsung-Chieh Shih, et al.
Published: (2020-12-01)

Evolution of cell therapy for renal cell carcinoma
by: Yufei Wang, et al.
Published: (2024-01-01)

Clinical trials of cellular therapies for the treatment of colorectal cancer: a narrative review
by: A. Hosseini Abgir, et al.
Published: (2023-09-01)

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies
by: Haiqiong Zheng, et al.
Published: (2024-11-01)

CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings
by: Zeljko Todorovic, et al.
Published: (2022-05-01)

Scalable process development of NK and CAR-NK expansion in a closed bioreactor
by: Xuening Wang, et al.
Published: (2024-07-01)

Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases
by: Alejandrina Hernández-López, et al.
Published: (2025-01-01)

Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pancreatic ductal adenocarcinoma using computational approaches
by: Prasanna Srinivasan Ramalingam, et al.
Published: (2024-10-01)

Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma
by: Jingjing Pu, et al.
Published: (2024-10-01)

Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
by: Tadesse Asmamaw Dejenie, et al.
Published: (2022-11-01)

GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma
by: Lili Guan, et al.
Published: (2024-09-01)

Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers
by: Manuel Gotti, et al.
Published: (2020-10-01)

TET2 downregulation enhances the antitumor efficacy of CD19 CAR T cells in a preclinical model
by: Yeongrin Kim, et al.
Published: (2025-02-01)

A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform
by: Susann Albert, et al.
Published: (2017-04-01)

Linker-specific monoclonal antibodies present a simple and reliable detection method for scFv-based CARNK cells
by: Katharina Schindler, et al.
Published: (2024-09-01)

CAR-T cell therapy: cell reprogramming to combat malignant neoplasms
by: Soares, José Eduardo Palacio, et al.
Published: (2022-08-01)

Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort
by: Emma Rabinovich, et al.
Published: (2021-12-01)

CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
by: Lusine Hovhannisyan, et al.
Published: (2023-05-01)

CAR-based cell therapy: evaluation with bibliometrics and patent analysis
by: Yajun Yuan, et al.
Published: (2021-11-01)

Road testing new CAR design strategies in multiple myeloma
by: Priyanka S. Rana, et al.
Published: (2022-08-01)

Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells
by: Nicole Cordes, et al.
Published: (2021-06-01)

Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients
by: Silvia Arcangeli, et al.
Published: (2020-06-01)

Cell membrane patches transfer CAR molecules from a cellular depot to conventional T cells for constructing innovative fused-CAR-T cells without necessitating genetic modification
by: Jing Hu, et al.
Published: (2024-08-01)

From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma
by: Jin Zhao, et al.
Published: (2024-05-01)

CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review
by: Ler Yie Chan, et al.
Published: (2022-03-01)

Novel insights into cancer stem cells targeting: CAR-T therapy and epigenetic drugs as new pillars in cancer treatment
by: Veronica Veschi, et al.
Published: (2023-05-01)

Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration
by: Alice Sýkorová, et al.
Published: (2024-09-01)

CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
by: Xiaomin Zhang, et al.
Published: (2023-02-01)